STACKDSTACKDResearch
Sign up

STACKD summary

Limited human data

AOD-9604: an old GH-fragment idea

Early fat-metabolism research that modern therapeutics have outrun.

Fat loss

Plain-language summary

AOD-9604 is a fragment of human growth hormone (the 176-191 region) that was investigated for fat metabolism without the full anabolic profile of intact GH. Some early human and preclinical work explored fat-loss endpoints, but the results have been mixed and modest, nowhere near the consistency or effect size of today's incretin therapies.

What was studied

Early human and preclinical studies of AOD-9604's effects on carbohydrate and lipid metabolism, examining whether the fragment could drive lipolysis-related endpoints.

Key takeaways

  • The concept was a GH-derived fragment aimed at fat metabolism without broad GH agonism.
  • Early human exploration exists, so it's tagged “limited human”, but the base is older and mixed.
  • Effect sizes did not hold up against modern obesity therapeutics in later comparisons.
  • Historically interesting more than practically compelling today.

Limitations & what we don't know

  • The evidence base is older, smaller, and inconsistent.
  • Not a substitute for lifestyle changes or approved obesity therapies.
  • Gray-market product authenticity is a recurring diligence issue.
  • No modern large RCTs establishing meaningful fat loss.

Sources

Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.

  1. 1.